Sign Up to like & get
recommendations!
0
Published in 2017 at "Drugs"
DOI: 10.1007/s40265-017-0708-2
Abstract: Daclizumab (Zinbryta®; previously known as daclizumab high-yield process) is a therapeutic monoclonal antibody that has recently been approved for the treatment of relapsing forms of multiple sclerosis (MS) in adults. Daclizumab is a humanized IgG1…
read more here.
Keywords:
daclizumab;
multiple sclerosis;
review relapsing;
daclizumab review ... See more keywords